PHASE 3 Study Drug May Help Manage Tardive Dyskinesia

The Segal Institute is excited to participate in an important research study of a phase III drug that may help manage Tardive Dyskinesia (TD).  By participating in this research, we may help bring much-needed new treatments to our patients living with TD.  Made up of nine sites throughout South Florida and South Carolina, the Segal …

Read more

Want more information?

Join our

Be the first to know about our new studies! You can unsubscribe at any time.